rimexolone
Trade name: vexol
Approved
Dec 30, 1994
Rimexolone is a glucocorticoid receptor agonist. Rimexolone ophthalmic (for the eyes) is used to treat eye inflammation caused by infections, injury, surgery, or other conditions. It is FDA approved for the treatment of post-operative inflammation and anterior uveitis. Common adverse reactions include hypotension, erythema, pruritus, taste sense altered, headache, blurred vision, discharge from eye, pain in eye, pharyngitis, and rhinitis. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 2 marketing orgs
Earliest trial started Jul 1, 2006 (NCT00471419)
Timeline
1990s
- Dec 30, 1994
Eyevance — Earliest FDA Approval
- Dec 30, 1994
Eyevance — NDA Organization
- Dec 30, 1994
Eyevance — NDA Secondary Org
- Dec 30, 1994
Harrow Health — Marketing Organization
2000s
- Jan 1, 2006
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Approval history
- approvedPriority reviewDec 30, 1994
Chemistry & pharmacology
SMILES
CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C- Mol. weight
- 370.525 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaRimexolone ↗
- NCATSO7M2E4264D ↗
- ChEMBLCHEMBL1200617 ↗
Also known as
- (11 beta,16 alpha,17 beta)-11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)androsta-1,4-dien-3-one
- 11 beta-hydroxy-16 alpha,17 alpha,21-trimethylpregna-1,4-diene-3,20-dione
- org 6216
- org-6216
- org-6216
- org-6216
- rimexel
- rimexel
- rimexolon
- rimexolon
- rimexolone
- rimexolone
- rimexolone
- rimexolone
- rimexolone
- rimexolone
- rimexolone
- rimexolone
- rimexolone
- rimexolone
- rimexolone
- trimexolone
- vexol
- vexol
- vexol
- vexol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02816905 | Phase 4 | Oct 1, 2015 | Cairo University |
| NCT00471419 | Phase 3 | Jul 1, 2006 | Alcon |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alcon | For profit | 1 | 1 | 1 | 2006 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2015 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eyevance | For profit | NDA | Dec 30, 1994 |
| Eyevance | For profit | NDA2 | Dec 30, 1994 |
| Harrow Health | For profit | MKTG | Dec 30, 1994 |